In 2006, the Moffitt Cancer Center partnered with patients,
C ancer is the second leading cause of death in the United States, affecting 1 in 2 men and 1 in 3 women in their lifetime, with an estimated 1.6 million new cases and more than 572,000 deaths annually based on the 2011 statistics. 1 The total cost of cancer to the United States each year is $228.1 billion from treatment, morbidity, and mortality. 2 The numerous advances in genomics technologies and translational research are swiftly increasing our knowledge about the biological basis of diseases such as cancer and thereby creating, for the first time in human history, the opportunity to translate these laboratory discoveries into personalized medicine. The goals of personalized medicine were highlighted by Health and Human Services Secretary Kathleen Sebelius, ''Iwhen doctors can truly prescribe the right treatment, to the right person, at the right time, we will have a new level of precision and effectiveness that will provide the knowledge-driven power that is necessary to achieve our highest goals in health care reformVincluding more effective disease prevention and early disease detection.'' 3 Many examples of tailoring treatments using genetic information for individual patients already exist for various cancers, such as chronic myelogenous leukemia and the bcr-abl inhibitor imatinib, 4 nonYsmall cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitors such as erlotinib 5 or gefitinib, 6 and melanoma and the BRAF inhibitor vemurafenib. 7 However, the successful implementation of a personalized medicine strategy must consider factors that are much broader than only genetic information; it must also incorporate environmental, family history, socioeconomic, and other risk factors to affect an improvement in the quality of care.
The Moffitt Cancer Center (MCC) has created an approach to deliver personalized medicine called Total Cancer Care (TCC) that leverages partnerships with patients, community clinicians, industry, and academia to focus on new technologies to improve screening methods, define new standards of care, and develop new therapeutic technologies and methods based on genomics, biomedical engineering, and information technology principles. 8, 9 The TCC Protocol (TCCP) was established to enable researchers and caregivers to identify and meet all the needs, including treatment and psychosocial-related needs, of a patient and his or her family during the patient's lifetime (Fig. 1) . The TCC is a prospective, observational study with a goal of recruiting hundreds of thousands of patients who participate in several ways: patients agree to (1) be followed throughout their lifetime and release medical data for research; (2) allow use of tissue samples for research that will molecularly characterize cancer diseases, personalize cancer care and treatment, and reveal targets that can be exploited for the development of new treatments; and (3) to be recontacted if a new finding is discovered that could influence their care, including clinical trials. 10 Although the TCCP was conceived by the MCC, the sheer scope of the project required the creation of a consortium network composed of 10 Florida hospitals (including MCC) and 8 national sites. The consortium network sites recruit patients to the TCC observational study, ship tissues to MCC for molecular analysis and banking, and provide medical data about their TCC study consented patients for integration into a data warehouse ( Fig. 2 ). In addition, the consortium network is able not only to enroll patients in the TCC protocol but to contact patients who are eligible for clinical trials at multiple sites across the network to both increase patient accrual and deliver investigative treatments locally to the patients. To integrate the plethora of information captured through the TCC consortium and affiliate networks, a state-of-the-art data warehouse is being developed that permits access to data for patients, researchers, and clinicians using several strategies.
Recognizing that there are several stakeholders in creating the infrastructure for personalized medicine with an emphasis on cancer care and research, MCC sought to partner with many potential stakeholders, including the pharmaceutical industry. By leveraging a partnership with Merck Pharmaceuticals, and with generous support from the state of Florida, Hillsborough County, and the city of Tampa, MCC launched a new corporation called M2Gen to help implement and manage the TCC consortium and support the discovery of molecular signatures to allow the right care, for the right patient, at the right time. Key to the success of this endeavor are ongoing efforts to invite and consent 100s of thousands of cancer patients and collect tumor material, blood, detailed personal medical histories, and outcomes data throughout the patient's lifetime. This resource will be one of the largest and most complete clinically annotated biobanks in the world; galvanized by information technology that will enable the discovery of evidence-based treatments for the betterment of cancer patients.
The creation of an infrastructure to support the discoveries and translation of personalized cancer treatments and the ability to identify preemptive measures to prevent and detect cancer is not inexpensive or quickly done. In fact, such a structure, by its very nature, must be continuously revised through an ongoing system of learning. The various components are outlined below as the framework established to support TCC to-date, including the process of informed consenting, biospecimen collection, and data management. Also outlined is the data warehouse to support TCC, which is evolving into a research information exchange (RIE) as well as the processes created to ensure regulatory compliance and high-quality access to data by multiple stakeholders: patients, researchers, administrators, and clinicians ( Fig. 3 ).
THE TOTAL CANCER CARE PROSPECTIVE STUDY

Execution of the Project Goals
To accomplish the collaboration's objectives, MCC created a protocol that collects tumor samples and clinical data under the umbrella of a single protocol (TCCP). The TCCP is a prospective longitudinal outcomes study that requests the patients' permission to (1) follow them for their lifetime, (2) access their tumor, and (3) to recontact them in the future for additional studies such as a therapeutic clinical trial. With the oversight of MCC, the study is administered through MCC's subsidiary M2Gen. M2Gen's workforce, dedicated to the advancement of personalized medicine, is responsible for the execution of the TCC protocol initiation/education, monitoring, biobanking of protocol-collected tissue, and the coordination of the TCCP Consortium investigators to ultimately perform clinical trials that leverage the TCCP database. The protocol is approved by the institutional review board at each site, and a harmonized consent is used.
Electronic Implementation of Informed Consent
To facilitate the standardization and rapid data collection of the consent across eighteen sites, MCC developed an electronic version of the informed consent to establish an electronic consenting process. Currently being used by several consortium sites, patients who are offered participation in the TCCP are given the opportunity to view a video explanation of the study. This 5-minute video presentation was narrated by the principal investigator of the TCCP and was approved by local institutional review boards for use. It contains all the required elements of informed consent as set forth by the U.S. Food and Drug Administration and is available in both English and Spanish. For the sites using the electronic consenting, the informed consent process begins with a personal contact from a TCCP coordinator who is also present throughout the process to answer any of the patients' questions. Interested patients are presented with a computerized tablet that was developed by Galvanon, Inc, an NCR Corporation company. This tablet contains a video FIGURE 3 . The TCC data warehouse has been designed to serve multiple stakeholders providing researchers with integrated clinical, molecular, and research data for basic, population, and clinical sciences; a patient view that delivers personalized health care data through a patient portal and provides researchers and clinicians with an interactive tool through the use of questionnaires and other electronic interfaces; an administrative view that enables quality and safety improvements through various interfaces and is the foundation for meeting the meaningful use criteria; and a clinician view that will deliver decision support tools based on evidence-based guidelines and rapid learning systems to match the right treatment, to the right person at the right time. presentation, as well as an electronic copy of the Informed Consent and Research Authorization form that is prepopulated with the patient's identifiers and encounter date. If the patient decides to participate in the study, verification of name on the Informed Consent and Research Authorization form is requested, as well as the patient's signature on the Galvanon tablet. For Moffitt patients, the fully executed Informed Consent and Research Authorization is automatically uploaded into the patient's electronic medical record, and a copy is printed for the patient to take home. Patients who decline or defer participation until a later date are also noted in the Galvanon system.
Currently, consent data are reviewed for accuracy throughout the TCCP consortium by clinical research monitors used by M2Gen. The monitors verify that the informed consent process is executed and recorded appropriately and that consented subjects meet study eligibility criteria. The Moffitt Compliance Department provides guidance to the clinical research monitors. At MCC, the Moffitt Clinical Trials Office performs quality assurance checks on a random 10% of subjects consented by each TCCP study coordinator at Moffitt. As a final validation of the electronic consent, postcards are mailed to each consented subject at MCC to thank him/her for his/her participation in TCCP. A contact number is provided to allow patients to call if they question the validity of their consent.
Biobanking and Biorepository
Since the protocol's inception in February 2006 up to June 28, 2011, more than 76,434 patients have been consented to participate, resulting in greater than 23,069 human biospecimens cases being banked, from which more than 14,000 tissues have been gene expression profiled.
The evolution from a passive function of pathology to an integrated, proactive process required significant investment and planning. Processes and standard operating procedures (SOPs) were developed for the collection, processing, storage, and quality control of tissues. In addition, sizable investments in developing facilities, equipment, and infrastructure established a biorepository capable of generating richly annotated, high-quality biospecimens to support cancer research efforts (Table 1) .
Facilities
To accommodate the thousands of biospecimens collected annually, a dedicated laboratory space was built. An 11,400-ft 2 facility was opened in 2008 that serves as a centralized biorepository hub for processing, storage, annotation, and shipment for all TCCP biospecimens. This includes specimen storage and more than 1800 ft 2 has been dedicated for pathology quality review stations, data abstraction, and biorepository administrative offices.
Moffitt and M2Gen invested in an automated ultralow temperature (j80-C) freezer system from Nexus Biosystems (San Diego, CA). This system facilitates efficient management of thousands of tubes, and the automated sample retrieval system significantly reduces the impact of unwanted freezeYthaw cycles on archived biospecimens. With only the sample(s) of interest retrieved, this practice safeguards the archived samples to ensure high-quality preservation of frozen biospecimens. The more than 2100-ft 2 automated freezer system has a capacity to store more than 2.5 million bar-coded tubes. This system provides nearly instantaneous access to stored biospecimens and is capable of handling and retrieving thousands of tubes per day. Biospecimens stored in this freezer primarily consist of snapfrozen tissue, blood, and blood derivatives such as plasma or nucleic acids.
TCCP PROCESSES AND SOPS TCCP Biospecimens
The TCC informed consent allows for the collection of excess tissue removed at the time of surgery and for the collection of blood (È15 mL) as part of a patient's regular blood draw. In addition, the consent provides permission for subsequent blood draws each year the patient is followed. Likewise, patients provide consent to obtain extra biopsy material for research as part of the patient's regular treatment. Patients with hematologic disease undergoing bone marrow aspiration who consented to TCCP allow for an extra pass to be taken for research purposes. When available the TCCP consent allows for collection of associated clinical blocks (eg, paraffin-embedded tissue) and slides. Moffitt has several pathologists committed to the evaluation, annotation, and selection of tissues for research activities. Slides are evaluated and marked, with quality annotation data entered directly into the biospecimen system of record.
Total Cancer Care Protocol SOPs
Fresh-Frozen Tissue
Tissue samples are collected and snap-frozen in liquid nitrogen within 15 minutes of surgical extirpation. Because of the difficulty of recording warm ischemic times, only cold ischemic times are collected, which are typically less than 5 minutes. Snapfrozen tissues are then recorded, labeled, packaged, and placed in a quarantine status at each TCCP collection site for 14 days. The quarantine period allows a window for pathology to recall the specimen if needed for patient care. After the 2-week window closes, wherein typically the final pathology report is issued, the frozen samples are shipped on dry ice to the TCCP biorepository for further processing.
Upon receipt, a frozen section is prepared for each tumor specimen and is stained by hematoxylin and eosin staining (H&E). The H&E slide is submitted to a pathologist's review where each tumor specimen is scored for various characteristics such as percent of stroma, malignancy, necrosis, and normal. This quality assurance and quality control step is referred to as pathology quality control and ensures that the histology of the tumor agrees with the pathology report accompanying each collected tumor sample. This information is entered into the biorepository's biospecimen inventory management system of recordVLabVantage Biobanking (Bridgewater, NJ).
As part of the pathology quality control assessment, the pathologist marks each slide precisely for tumor composition, which serves as a guide for the macrodissection of each tumor sample. The macrodissection is performed in liquid nitrogen to maintain the tissue frozen. On completion of macrodissection, the enriched tumor is weighed and then transferred into a twodimensional bar-coded tube and stored in the automated j80-C freezer system. Finally, annotation of each tumor specimen is completed using the pathology report and is modeled based on College of American Pathologists standards.
Biopsies
A pathologist or cytotechnologist capable of assessing sample adequacy facilitates sample collection during imageguided biopsy procedures. Once the standard-of-care specimen yield is satisfied, additional core needle or fine-needle biopsy passes are taken for research. In cases of image-guided biopsy collections, the tissue is typically placed into preservative media within 5 minutes.
Depending on the procedure being used to collect the samples (fine-needle aspiration or core-needle biopsy), slides generated can be touch preps, smears, or cell suspensions. These slides can be stained at the site, where cytology support is available, or left unstained and sent to the TCCP Biorepository with the samples. Upon receipt, unstained slides are prepared for each tumor specimen and stained by H&E, Diff-Quik, or Papanicolaou. The slide(s) is subjected to a pathologist review (pathology quality control) where each tumor specimen is scored similar to frozen samples.
Blood Collection and Processing
For logistical reasons, currently, collection of TCCP blood is only performed at the MCC. Standard practice for blood banking simply involves freezing a 7-mL EDTA tube within 30 minutes at j80-C. Blood tubes are processed on-demand for subsequent project-based DNA extraction. In addition, the TCCP has the ability on demand to process blood for plasma, buffy coats, or cell pellets.
Bone Marrow Collection
Bone marrow collection focuses on aspirates from TCCP patients identified as potentially high tumor yield. Samples are processed for mononuclear cells under SOPs developed by the Biorepository. In addition, each sample is pathologist annotated for 12 discreet values such as cell count and diagnosis.
Biospecimen Inventory Management
Tracking and managing the TCCP Biorepository is done within LabVantage Biobanking software (LabVantage). LabVantage biospecimen data serve as one of the major source systems feeding the TCCP data warehouse. One of the most important value-added features is its end-to-end biospecimen tracking capabilities. This includes new study initiation support, consent verification, biospecimen collection and accessioning, support for sample processing steps, sample release, and biospecimen storage mapping.
Quality Metrics
M2Gen has established consistency in accruing highquality tumor and matched normal adjacent specimens. M2Gen tissue sample processing results in products useful for large-scale and large sample size Affymetrix GeneChip analysis, copy number variation/single nucleotide polymorphism (SNP) and whole Exome sequencing analysis, and phospho-proteoomic analysis. After macrodissection, the tumor samples undergo RNA and DNA extraction followed by a rigorous quality assurance and quality control process (Table 2 ).
DATA MANAGEMENT: CREATION OF AN RIE
Health care reform is transforming the way data and information are collected and used across the health care continuum in an effort to improve the quality of care, reduce errors, and allow patients to play a greater role in wellness and disease management. Much of the current momentum of personalized medicine is based on molecular technologies such as genomics and proteomics that are being used to develop new biomarker-based diagnostics and prognostic tools that will facilitate earlier detection of disease and biological monitoring of interventions. In addition, molecular-based technologies are creating new paradigms in the development of therapeutic drugs that target specific biological processes revealed through molecular characterization of the patient. Not all personalized medicine is molecular based, but the need to move to evidence-based personalized medicine requires the design of new information systems that enable the repurposing of data for multiple stakeholders. One foundation of TCC is a data warehouse that is rapidly evolving into a RIE that harmonizes and integrates data from the TCC consortium into a centralized data warehouse (the hub) using complex metadata structures exposed to the users via a searchable data dictionary (Fig. 4) . One component of the RIE is the data factory that is used as a repository for data extracted from source systems using the extract, transform, and load (ETL) process. Extracted data are profiled to determine the overall data quality, and data cleansing is performed to ensure that reliable data are loaded into the TCCP data warehouse. The principles of data accuracy, completeness, time-relatedness, consistency, accessibility, and integrity are central themes of TCC data management. In addition, any data transformations required are performed before loading into the data warehouse. One of the most important operations performed in the data factory is the concept of semantic integration. Total Cancer Care consortium data are generated from multiple sites and multiple source systems. The creation of semantically harmonized data is achieved through the use of a complex data dictionary that is created using metadata that aligns the use of data with collection and storage.
More specifically, metadata are structured information that describe, explain, locate, or otherwise make them easier to retrieve, use, or manage an information resource. There are 2 main types of metadata: contextual and physical. Contextual metadata are descriptive metadata that include the definitional, permissible values, and other features that explain the context of the data element. Physical metadata are the administrative part of metadata that include the source system of the data, data transformations, and structural metadata that describe the physical or logical structure of complex objects such as versions or relationships. 11 Automated capture of the physical metadata during ETL processes provides a method for maintaining data provenance, which is critical when analyzing complex data sets.
There are many reasons TCC is adopting a rigorous metadata strategy. First, many times, the end users of a data system are not sophisticated technologists or IT professionals who understand the underlying data structures and how to use languages such as SQL to retrieve data from databases. A comprehensive metadata layer facilitates the development of ''friendly'' end user interfaces. Metadata also provide strategies for organizing data in multiple ways such as by audience (data that will be used for a patient portal) or by topic (cancer subtypes based on molecular biomarkers). Using the contextual metadata layer allows for easy repurposing of data using database views and downstream data marts. The MCC generates contextual metadata working with subject matter experts (SMEs) who originally digitized the data. There are many data standards that already exist, such as SNOMED CT, ICD-10, LOINC, or MedDRA, and these are leveraged to streamline the metadata creation process. Mapping data standards to existing data sets that may have strong or weak correlations with these standards is also challenging and time-consuming and requires SMEs. With the assistance of data stewards, SMEs and information professionals create or map contextual metadata to existing data from the TCC consortium. The IT professionals who manage these data create and capture the physical metadata layer.
Understanding these data is fundamental to its design, harmonization, standardization, reuse, and interchange. 12, 13 This requires the establishment of a data framework that defines each data element discretely and associates the appropriate metadata FIGURE 4 . The TCC RIE has 3 major components. First are the source systems that makeup the information technology infrastructure at the MCC and TCC consortium sites. Selected data from these systems are moved, using ETL methods, to populate a data factory where data can be harmonized and integrated before loading in the TCC data warehouse. From this point, data can be repurposed for multiple stakeholders and projects to support translational research and personalized medicine.
to fulfill the use cases of health care organizations. An important resource toward this goal is the establishment of a data dictionary that is able to capture the contextual and physical metadata. The TCC data dictionary includes some of the following in a very formal structure:
1. The common data element (CDE) concept is outlined in the ISO/IEC 11179 standard that defines data elements as having 2 components: the data element concept and representation (value domain, data type, or units of measure). 13 The creation of CDEs based on the ISO/IEC 11179 standard allows for multiple versions of the truth in the TCCP data warehouse due to the individualized nature of the data elements coming from multiple sources. One guiding principle is that CDEs are not reused unless the concept of that CDE is exactly applicable in the data source; meaning the data element concept and representation are equal. The ISO/IEC 11179 standard is used to define data elements such that metadata registry standards can describe a wide variety of data. Once the data have been defined within a standard, the additional attributes or metadata are organized within the TCC data dictionary. This includes creating unique identifiers for research to adhere to Health Insurance Portability and Accountability Act regulations, alternate data types, how the data elements relate to standardized vocabularies and ontologies, the source information, and other attributes. This provides great flexibility in ways that data can be retrieved and used, creating a user-friendly data environment.
Once the data processing is completed in the data factory, those data are moved to the data warehouse that adheres to a third normal data structure 14 and acts as the hub for further data dissemination. To allow for the greatest flexibility in the use of TCC data, a ''hub-and-spoke'' model has been developed, which allows data from the hub (ie, the centralized aspect of the data warehouse) to be integrated with other data collected by research programs (ie, the spoke-level data that enhances the core warehouse data) or data entered by patients, creating a personal health record as examples (Fig. 5 ). This model also allows for data to be delivered in different ways, such as data marts, dashboards, or canned reports depending on the end user requirements. One challenge of this centralized/decentralized model is the need for strict data governance to maintain the quality of the data in the data warehouse. Therefore, data from spoke databases must adhere to the data dictionary and metadata standards before spoke-level data can be repurposed for general use, by other end users, in the TCCP data warehouse.
The RIE must also take advantage of other data available that relate to TCC such as genomic data and annotation resources, external personal health records, collaborative research databases, and physicians not using a TCC consortium electronic medical record. The RIE is able to use Web services to link to external data sources, such as the National Center for Biotechnology Information, which allow researchers to access the latest information while not requiring these resources be managed and maintained locally. In addition, MCC is exploring new ways to integrate data from other health care provides and caregivers to continue the evolution of the RIE through the creation of comprehensive lon-gitudinal patient records through a federated network data model. 15 The RIE along with resources under development such as clinical pathways will form the foundation to create evidence-based guidelines for personalized cancer treatment and facilitate the development of rapid learning systems. 16 The creation of an RIE focused on personalized cancer care is just one aspect of the TCC study, but it is critical to the realization of translational research that will pave the way to personalized medicine. And the RIE will never be finished; it is imperative that this resource is flexible to integrate new data types and technologies to better serve the patients, researchers, and clinicians in the pursuit of the prevention and cure of cancer in the 21st century.
DATA ACCESS: THE INFORMATION SHARED SERVICE DEPARTMENT
Once data have been collected and aggregated into a TCCP data warehouse, procedures and tools for accessing the data must be developed to facilitate the utilization of the data by end users including clinicians, researchers, and administrators. To ensure standardization of data release, regulatory compliance, and resource efficiency, Moffitt created the Information Shared Services (ISS) Department, which administers release of data from the central data warehouse. Within the ISS Department resides the Data Concierge, which receives and processes requests for data, and the Project Management Office that coordinates the aggregation of data across sources systems when the requested data do not reside entirely in the central data warehouse.
The process by which data requests are fulfilled begins with the Data and Biospecimen Request Form, a Web-based tool that solicits specific information from the requestor. The form also FIGURE 5 . The hub-and-spoke model of the TCC data warehouse. The central hub, or data warehouse, is able to support multiple stakeholders and projects through the spokes, or data marts. In addition to data marts, a spoke can be composed of dashboards, database views or reports providing flexibility of data delivery. In addition, each spoke can integrate data not part of the TCC data warehouse allowing researchers, patients, and clinicians to add new data based on their needs. For data to move from spokes back to the hub, a data governance structure has been established to ensure spoke data adhere to the data standards established for the RIE.
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The Cancer Journal & Volume 17, Number 6, November/December 2011 includes a section for uploading regulatory approvals when appropriate. All requests for patient-level data must have undergone review by both Moffitt's Scientific Review Committee and the institutional review board at the University of South Florida. The Data Concierge reviews the institutional review boardY approved protocols to ensure that the requestors have received approval to obtain the information being requested and in close collaboration with the requestor, Moffitt's Tissue Core and the Departments of Biomedical Informatics, Data Quality and Standards, and Information Technology, the data sources are identified and data quality checks are performed before the final release of the data. All data releases are logged into a central tracking system to support project management and data usage reporting.
To facilitate the above process, several honest brokers have been established within Moffitt, including the ISS Data Concierge, Tissue Core, and Cancer Informatics Core. Individuals working within these groups have access to patient protected health information residing in multiple source systems. However, the release of information through the source systems is coordinated by the ISS Department, as described above. Given that some research programs are active users of the data, a programspecific honest broker policy has also been established, whereby a data concierge residing within ISS is dedicated specifically to the program. The program-specific honest broker is intimately familiar with data residing within the ''hub,'' as well as the specific program or ''spoke'' in which he or she is working. Although the program-specific or ''spoke-level'' honest broker's daily activities are directed by the research program leader, he or she officially reports to the Director of ISS and logs all spoke-level data requests into the central ISS data request tracking system. The spoke-level honest broker may also contribute subject matter expertise during database development and integration of spokelevel data back into the hub.
The data release process and honest broker policies outlined above comprise an efficient approach to providing high-quality patient-level data to requestors. However, investigators often require aggregate data or ''counts'' in preparation for research. Enabling the investigators to directly query deidentified data residing in the central database is the most efficient approach toward ''cohort identification.'' As such, Moffitt is configuring a frontend tool that allows investigators to identify groups of patients based on a set of parameters defined by variables residing in multiple source systems. Once the investigator identifies a cohort and receives regulatory approval, he or she completes the Data and Biospecimen Request Form to gain access to the patientlevel data.
To effectively address the multitude and complexity of issues that arise in conjunction with the storing and dissemination of data, Moffitt has instituted a data governance structure emanating from a Steering Committee of leadership and stakeholders, and function-specific subcommittees that address various aspects of operational decision making. The subcommittees are defined around foci of subject-matter expertise and meet monthly to discuss topics including information technology support of TCC, data acquisition, data standards and release, biobanking SOPs, and management of the TCC protocol itself. Recommendations made by each subcommittee are reviewed for approval by the TCC Steering Committee, which authorizes action, allocates resources when necessary, and ensures that the overall activities of each committee are well coordinated and collectively advance the institution toward its goals of personalized medicine.
Impact of TCC
Total Cancer Care is a maturing resource that has proved invaluable to cancer researchers, industrial partners, and pa-tients. Examples include the following: (1) Research by Srikumar Chellappan and colleagues are using tissues and data from TCC to correlate levels of specific transcription factors with expression of genes related to cancer progression and metastasis, as well as examining a cancer stem cell signature and its correlation with patient outcomes in lung cancer. 17, 18 (2) A research group led by Javier Torres-Roca investigating a predictive model of clinical response to concurrent radiochemotherapy is using the TCC data warehouse to validate the clinical response. 19 David Fenstermacher is leading a research team to create new information infrastructure to extend the usability of the TCC data warehouse for comparative effectiveness research using the data from TCC consented patients to develop new data models and software tools. Several comparative effectiveness research studies in myelodysplastic syndromes have been undertaken based on this work 20 (Craig et al., unpublished data). (3) Jonathan Strosberg used the TCC data warehouse to search for eligible patients for a phase II clinical trial in CRC metastatic disease. The trial, from the letter of intent to the last patient treated (n = 37), was completed in just more than 10 months. This ''game changer'' demonstrates the value of large cohorts that can be screened for inclusion criteria, including molecular data, to design and execute not only targeted trials but also faster and less expensive trials using efficient patient-trial matching (Strosberg et al., unpublished data). (4) Merck and Company is using TCC resources for biomarker and new drug target discovery. (5) The MCC has created a patient portal that provides patients access to their own medical history as well as a survivorship plan that details how each patient should monitor his or her disease for relapse. Additional functionality includes a comprehensive electronic patient questionnaire, access to high-quality cancer information provided by the LIVESTRONG Foundation, and the ability to schedule and manage health care visits to Moffitt.
SUMMARY
The MCC has been developing the TCC study for more than 5 years and has created the necessary infrastructure to support patient consent, biobanking, data collection, and storage and provide several levels of access to information for multiple stakeholders. To realize the promise of personalized medicine, researchers and clinicians are partnering to create evidence-based guidelines in the form of clinical pathways that provide detailed decision trees that outline treatment options based on the molecular and clinical characteristics of each patient's cancer disease. The challenge is to transform data into knowledge and ultimately wisdom to better inform and guide patients and clinicians to raise the standard of care and improve quality of life for those affected with and by cancer.
